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The pathogenic mechanisms driving Sjo¨gren’s syndrome (SS) are unclear. In this issue of Immunity,
Okuma et al. (2013) demonstrate that tissue-specific dysfunction, namely deficiency of the transcriptional
regulator IkB-z in epithelial cells, rather than hematopoietic cell pathology, is sufficient to elicit SS-like
inflammation.Sjo¨gren’s syndrome (SS) is a common
chronic inflammatory autoimmune dis-
ease characterized by the impaired func-
tion of exocrine glands, mainly the salivary
and lacrimal glands, based on chronic
mononuclear infiltrates that ultimately
lead to the destruction of the glandular
structures (Ramos-Casals et al., 2012).
Hallmarks of the disease are persistent
oral (called xerostomia) as well as ocular
(named keratoconjunctivitis sicca) dry-
ness. SS can develop alone, referred to
as primary Sjo¨gren’s syndrome (pSS), or
in conjunction with other associated auto-
immune diseases such as systemic lupus
erythematosus, then termed secondary
Sjo¨gren’s syndrome (sSS). Complica-
tions in SS include the involvement of
other glandular and extraglandular organ
systems as well as an increased risk of
developing non-Hodgkin’s lymphoma
(Ramos-Casals et al., 2012). Besides
lymphocyte infiltration, the pathogenic
features of SS include the generation
of specific serum autoantibodies, most
prominently the anti-ribosomal antibodies
such as anti-SSA (anti-Ro) and anti-SSB
(anti-La), which serve as markers for
establishing clinical diagnosis. Despite
its great clinical relevance, little is known
about the pathogenesis of SS. Animal
models accurately mimicking sponta-
neous tissue-specific disease exhibiting
the characteristic features and diagnostic
findings of the autoimmune pathology are
amiss, reflecting our lack of insight into
the pathogenic mechanisms driving
and molecular defects underlying this
disorder. There exist a few animal models
recapitulating pathology reminiscent of
SS (Groom et al., 2002; Guo et al.,
2011; Peng et al., 2010). Thus far, these404 Immunity 38, March 21, 2013 ª2013 Elsemodels have focused mainly on SS-like
pathology as a secondary disease seen
in association with other disorders or on
pathologies in effector cells of the
immune response, namely T and B cells,
rather than factors in the local environ-
ment in which autoimmunity occurs,
thus yielding findings which indicated
that aberrantly activated lymphocytes
might be catalysts and thus triggers of
SS-like disease (Groom et al., 2002; Guo
et al., 2011). However, some observa-
tions have implicated the involvement
of dysfunctions in the NF-kB signaling
pathway in disease pathogenesis (Peng
et al., 2010).
The nuclear factor kappa B (NF-kB)
family of transcription factors controls
numerous genes involved in cell survival
and proliferation and innate and adaptive
immune reactions, making it a key player
in inflammatory responses. Dysregulation
and chronic activation of the NF-kB
pathway play a role in pathogenic mecha-
nisms in numerous diseases such as
cancer, autoimmunity, and chronic in-
flammation (Raasch et al., 2011; van Loo
et al., 2006). NF-kB activity is tightly
controlled at different levels by a number
of regulatory elements, allowing for
context-specific responses. The induc-
ible kinase B (IkB) protein family is com-
prised of various multifaceted, complex
regulators of NF-kB transcriptional
activity including IkB-z, which is encoded
by the Nfkbiz gene. The classical IkB
proteins are constitutively expressed
and present in the cytoplasm under
resting conditions, forming complexes
with NF-kB dimers, thus regulating their
function (Yamazaki et al., 2001). In
contrast, IkB-z is induced by proinflam-vier Inc.matory stimuli and regulates DNA binding
of NF-kB without inhibiting its nuclear
translocation. Thus, IkB-z specifically
modulates NF-kB activity induced by
inflammatory stimuli, thereby possibly
preventing undesirable excessive inflam-
matory reactions (Yamazaki et al., 2001).
IkB-z is able to selectively activate or
impede specific NF-kB activity, thus
being implicated in both cell survival and
apoptosis (Motoyama et al., 2005). Addi-
tionally, IkB-z appears to be essential for
efficient Th17 cell development, making
IkB-z-deficient (Nfkbiz/) mice resistant
to experimental autoimmune encephalo-
myelitis (Okamoto et al., 2010).
In this issue of Immunity, Okuma et al.
(2013) made use of Nfkbiz/ mice and
show that they exhibit hallmark character-
istics of SS-like autoimmune disease
such as lymphocytic inflammatory infil-
trates of the lacrimal glands with reduced
tear secretion and production of the
characteristic anti-ribosomal antibodies
anti-SSA and anti-SSB. In order to identify
the IkB-z-deficient cell type mainly
responsible for the development of
the SS-like phenotype, the authors under-
took a series of well-designed experi-
ments employing both newly generated
cell type-specific IkB-z-deficient mice
as well as lymphocyte-deficient mice
(Nfkbiz/Rag2/). Whereas activated
lymphocytes proved to be essential
for the initiation and/or progression
of disease, adoptive transfer experi-
ments told a different story for IkB-z
deficiency. Ocular inflammation could
be induced in Nfkbiz/Rag2/ mice
regardless of whether IkB-z-deficient
or -competent cells were transferred.
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Figure 1. Increased Apoptosis in IkB-z-Deficient Epithelial Cells Causes SS-like Pathology
The abrogation of STAT3-mediated IkB-z signaling in epithelial cells most probably causes changes in the
transcriptional activity of NF-kB. NF-kB is activated upon inflammatory signaling, leading to increased
caspase-3 processing and ultimately increased apoptosis in epithelial cells, which precedes and most
likely elicits SS-like pathologywith lymphocytic infiltration and SS-specific ribosomal antibody production.
Treatment with caspase inhibitors greatly reduces these effects, dramatically diminishing inflammatory
lesions while augmenting tear secretion, corroborating the finding that excessive apoptosis in epithelial
cells in the absence of IkB-z is a trigger and thus responsible for the development of SS-like disease.
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recipient mice (Nfkbiz+/+Rag2/) in iden-
tical cell transfer experiments. Thus,
although lymphocytes are required for
the development of inflammation in
SS-like pathology, IkB-z deficiency in
lymphocytes is not essential. This finding
was corroborated by the fact that cell
type-specific IkB-z deficiency in T and B
cells in specific Cre-expressing lines
also did not lead to disease development.
Myeloid cells as IkB-z-deficient triggers of
SS-like disease were also ruled out
because myeloid cell-specific deficiency
of IkB-z (LysM-Cre;Nfkbizflox/flox) did not
bring about inflammation. Taken together,
these findings indicated a role for nonhe-
matopoietic cells.
Might tissue-specific cells, in this case
the glandular epithelial cells, rather than
the immune system itself be both the
victim and at the same time the culprit in
this case? The tissue specificity of SS
disease does indicate that dysfunctions
of local environmental factors and regula-tory mechanisms might act as catalysts
for an immune response. Indeed, mice
lacking IkB-z solely in epithelial cells (K5-
Cre;Nfkbizflox/flox) exhibited inflammation
similar to those with complete IkB-z
deficiency (Nfkbiz/). But what exactly
served as the trigger for an attack of
the immune system on IkB-z-deficient
epithelial cells? Upon closer observation,
an increase in apoptosis and concomitant
upregulation of caspase-3 processing in
the lacrimal glands was found in both
epithelial-specific as well as complete
IkB-z-deficient mice when compared to
controls. Aberrant apoptosis has been
noted in various autoimmune pathologies
in which lymphocyte activation leads
to tissue destruction, including in the
exocrine glands of SS patients and animal
models with SS-like disease symptoms
(Peng et al., 2010). These observations
raised an interesting question: which of
the two pathologies came first, dysregu-
lated tissue apoptosis or lymphocytic
inflammation? Okuma et al. (2013) answerImmunity 3this crucial question by systematically
establishing a clear-cut cause and effect
relationship, thereby identifying an essen-
tial role for IkB-z in the pathogenesis of
SS-like autoimmune disease. IkB-z-defi-
cient epithelial cells exhibited increased
apoptosis even in the absence of lympho-
cytes, as evidenced in lymphocyte-defi-
cient mice. Apoptosis therefore seemed
not to be caused by inflamed leukocytes
but rather to precede and thus most
likely trigger the inflammatory process.
Caspase inhibitor treatment of mice with
IkB-z-deficient epithelial cells further
corroborated this causal relationship
by suppressing apoptosis and thereby
ameliorating autoimmune inflammation
while increasing tear production (Figure 1).
Furthermore, the authors uncovered an
upstream molecular mechanism respon-
sible for inflammatory IkB-z expression
by showing that mice with STAT3
deficiency in epithelial cells (K5-Cre;
Stat3flox/flox) had the same symptoms
as did epithelial-specific IkB-z-deficient
mice.
The work by Okuma et al. (2013) thus
constitutes a substantial contribution to
our understanding of autoimmune patho-
genesis. The study provides mechanistic
insights into SS-like inflammation by
uncovering tissue-specific pathologies
that can act as catalysts for inflammatory
autoimmune processes. Additionally,
their findings raise the obvious question
of which role IkB-z plays in physiological
tissue homeostasis in general and in
epithelial cells especially, and how this
function is disturbed to cause the onset
of autoimmune disease. Could IkB-z be
involved in other autoimmune conditions
such as systemic lupus erythematosus
and lupus-related neuropsychiatric disor-
ders? Moreover, the molecular mecha-
nisms underlying the signaling cascade
through which IkB-z exerts its functions
are touched upon by identifying STAT3
as an upstream activator and discussing
the possible involvement of epidermal
growth factor (EGF) in IkB-z induction.
However, it remains to be clarified in
which context and by which molecular
means STAT3-mediated IkB-z induction
takes place, how its activation leads to
apoptosis, andwhich apoptotic pathways
and molecules (extrinsic or intrinsic path-
ways that lead to caspase-3 activation)
are induced. Finally, there currently is
neither a known cure for patients with SS8, March 21, 2013 ª2013 Elsevier Inc. 405
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Previewsnor a specific treatment to permanently
restore glandular secretion, so these
exciting experimental data may open
new avenues for the treatment of this
devastating disorder. Thus, future studies
should investigate the significance of
STAT3-mediated IkB-z-dependent in-
creased apoptosis in human SS dis-
ease and other autoimmune pathologies
in which aberrant apoptosis has been
noted.
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In this issue of Immunity, Schweighoffer et al. (2013) report that full BAFF responsiveness in B cells requires
the tyrosine kinase Syk and that BAFF may co-opt components of the B cell receptor in transmitting its
survival signal.It is axiomatic to mammalian immune
system function that adequate popula-
tions of recirculating B and T lympho-
cytes bearing unique antigen-binding
receptors are maintained in peripheral
lymphoid organs. The maintenance of
mature B cells in this steady state
requires the continuous receipt and
appropriate processing of environmental
cues. There are two receptors expressed
by B cells that are crucial for maintaining
B cell survival in the periphery; the clon-
ally restricted B cell receptor (BCR) for
antigen and the general receptor for
BAFF (B cell activating factor; BLyS),
a member of the TNF superfamily of
receptors. Although originally considered
independent, the redundancy, intersec-
tion, and crosstalk between the signaling
pathways triggered by these two media-
tors of B cell viability have been matters
of debate over many years (Mackay
et al., 2010; Rickert et al., 2011). In this
issue of Immunity, Schweighoffer et al.make a dramatic addition to this topic
by providing compelling evidence that
BAFF signaling impinges on components
of the BCR itself and requires the
kinase Syk, a key enzyme downstream
of the BCR (Schweighoffer et al., 2013).
Thus our understanding of BAFF-driven
B cell survival appears to be incomplete
and the signaling pathways emanat-
ing from the BAFFR and BCR might
share common, crucial, ligand-proximal
elements.
BAFFR and BCR signaling are
complex and multifaceted, not all of
which are required for B cell survival
(Figure 1). Elegant experiments showed
conclusively that the survival com-
ponent of BCR signaling could be
substituted completely and exclusively
by a constitutively active form of the
lipid-metabolizing enzyme, phosphoi-
nositide-3-kinase (PI3K) (Srinivasan
et al., 2009). Survival signaling through
BAFFR, however, despite activatingPI3K, depends on the noncanonical
(or alternate) pathway of NF-kB (re-
viewed (Rickert et al., 2011)). Although
the intersections of these two path-
ways were reviewed recently (Mackay
et al., 2010; Rickert et al., 2011), it
is sufficient here to note the following.
First, activation of PI3K is necessary
and sufficient for BCR-mediated survival
and necessary but insufficient for
BAFFR-mediated survival. Second, acti-
vation of PI3K and ERK downstream of
BAFF is biphasic with early and late
peaks, the latter requiring noncanonical
NF-kB signaling (Otipoby et al., 2008;
Patke et al., 2006). Third, withdrawal of
BAFF or the BCR has different conse-
quences; BCR deficiency leads to rapid
loss of all B cells while loss of BAFF
leaves B1 cells in the peritoneal cavity
unaffected. Fourth, BCR stimulation is
required to upregulate BAFFR during
development, and fifth, the canonical
NF-kB pathway downstream of the
